Sugi Predict

Sugi Predict / Targets / MAPK4

MAPK4

Mitogen-activated protein kinase 4 · P31152 · MAPK4 on Sugi Atlas →

4,570 patent compounds predicted against MAPK4, 4,309 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2963866 SCHEMBL2963866 0.80 2/20
SCHEMBL1446583 SCHEMBL1446583 0.80 2/20
SCHEMBL1446406 SCHEMBL1446406 0.76 2/20
SCHEMBL1446409 SCHEMBL1446409 0.76 2/20
SCHEMBL1446147 SCHEMBL1446147 0.76 2/20
SCHEMBL1151056 SCHEMBL1151056 0.73 2/20
SCHEMBL1446351 SCHEMBL1446351 0.73 2/20
SCHEMBL1446353 SCHEMBL1446353 0.73 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2052117) 0.69 2/20
SCHEMBL828788 SCHEMBL828788 0.68 2/20
SCHEMBL3578798 SCHEMBL3578798 0.68 2/20
SCHEMBL672223 SCHEMBL672223 0.62 2/20
SCHEMBL3245680 SCHEMBL3245680 0.60 2/20
SCHEMBL3471800 SCHEMBL3471800 0.58 2/20
SCHEMBL2985829 SCHEMBL2985829 0.57 2/20
SCHEMBL2985832 SCHEMBL2985832 0.57 2/20
SCHEMBL1134152 SCHEMBL1134152 0.55 2/20
SCHEMBL1095081 SCHEMBL1095081 0.53 2/20
SCHEMBL1095083 SCHEMBL1095083 0.53 2/20
SCHEMBL2963863 SCHEMBL2963863 0.53 2/20

Clinical trials — most relevant to MAPK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma PHASE2RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix PHASE2COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
RASopathy Biorepository nanRECRUITING
Histiocytic Disorder Follow-up Study nanRECRUITING
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma nanCOMPLETED
Glutamate Supplementation in Young Men nanCOMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAPK4 binder may also engage these)

ProteinNameSimilarity
Q6P5G0 — 1.000 Q6P5G0 →
Q68UT7 — 0.984 Q68UT7 →
Q9ERH7 — 0.981 Q9ERH7 →
Q6ZW76 — 0.981 Q6ZW76 →
D4A7V9 — 0.981 D4A7V9 →
NEK11 Serine/threonine-protein kinase Nek11 0.980 landscape →
DDX20 Probable ATP-dependent RNA helicase DDX20 0.980 landscape →
EIF2AK4 eIF-2-alpha kinase GCN2 0.980 landscape →
STK32C Serine/threonine-protein kinase 32C 0.980 landscape →
Q9Z0G2 — 0.979 Q9Z0G2 →
Q9QZ05 — 0.979 Q9QZ05 →
Q8WP28 — 0.979 Q8WP28 →
O88866 — 0.979 O88866 →
P27704 — 0.978 P27704 →
Q9JJY4 — 0.978 Q9JJY4 →
HUNK Hormonally up-regulated neu tumor-associated kinase 0.978 landscape →
P0C218 — 0.978 P0C218 →
A4QNA8 — 0.978 A4QNA8 →
HIPK4 Homeodomain-interacting protein kinase 4 0.977 landscape →
Q0P5I2 — 0.977 Q0P5I2 →
Q8C0Q4 — 0.977 Q8C0Q4 →
Q5RD27 — 0.976 Q5RD27 →
Q86UZ6 — 0.976 Q86UZ6 →
Q8WNU8 — 0.976 Q8WNU8 →
O70551 — 0.976 O70551 →
Q61532 — 0.976 Q61532 →
A6H8H5 — 0.975 A6H8H5 →
P54265 — 0.975 P54265 →
Q9CZ62 — 0.975 Q9CZ62 →
Q3V016 — 0.975 Q3V016 →